Trials / Withdrawn
WithdrawnNCT04797468
A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor
A Phase 1 Clinical Study to Investigate the Safety, Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of HLX23 (CD73 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the CD73 inhibitor HLX23 alone is safe and effective in participants with advanced solid cancer.
Detailed description
An open-label, dose escalation, first-in-human, phase 1 clinical study to investigate the safety, tolerability and to determine the maximum tolerated dose and recommended phase 2 dose of HLX23 (recombinant anti-CD73 humanized monoclonal antibody) in patients with advanced or metastatic solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX23 | administered IV. |
Timeline
- Start date
- 2022-07-18
- Primary completion
- 2023-01-13
- Completion
- 2023-01-13
- First posted
- 2021-03-15
- Last updated
- 2023-01-17
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04797468. Inclusion in this directory is not an endorsement.